[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![fortunatrading1 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::990988001491615744.png) FortunaTrading [@fortunatrading1](/creator/twitter/fortunatrading1) on x 1365 followers
Created: 2025-07-01 22:26:36 UTC

$BMRN

2025 Revenue Guidance: #BioMarin projects 2025 revenues between $XXX billion and $XXX billion, indicating double-digit growth. Non-GAAP EPS is expected to be between $XXXX and $4.40, surpassing analyst expectations.

Q1 2025 Results: Total revenues reached $XXX million (+15% Y/Y), driven by a XX% increase in VOXZOGO revenues ($214 million) and an X% rise in Enzyme Therapies revenues ($484 million, with PALYNZIQ up 22%). Non-GAAP EPS was $XXXX (+59% Y/Y), and GAAP Net Income rose XXX% to $XXX million.

Long-Term Goals: BioMarin aims for $X billion in revenue by 2027 with a XX% Non-GAAP Operating Margin starting in 2026, supported by a mid-teen revenue CAGR through 2034


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1940175231374729304/c:line.svg)

**Related Topics**
[bmrn biomarin](/topic/bmrn-biomarin)
[eps](/topic/eps)
[$bmrn](/topic/$bmrn)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/fortunatrading1/status/1940175231374729304)